Nicholas Restifo

Company: Marble Therapeutics

Job title: Chief Medical Officer

Seminars:

Supercharging TIL Therapy with LNP-Based Neoantigen Vaccines: A New Era in Cancer Immunotherapy 1:45 pm

Developing cutting-edge lipid-based delivery systems designed to specifically activate T-cells through polyepitope vaccines designed to enhance immune responses against common malignancies Providing ‘Signal 1’ — precise T cell receptor binding — to trigger T cell proliferation, persistence, and tumor penetration to ensure effective cytotoxic activity against cancer cells Accelerating the time from bench to bedside…Read more

day: Conference Day One